Affimed N.V. Stock, NASDAQ:AFMD
Technologiepark, Im Neuenheimer Feld 582, Heidelberg, Baden Wuerttemberg 69120
Number of Employees: 163
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.